Targeted protein degradation and the enzymology of degraders
Abstract
Targeted protein degradation is an emerging strategy for drug discovery that employs small molecules to catalyze the ubiquitination of target proteins, ultimately causing their degradation by the proteasome. Current degrader designs employ hetero-bivalent molecules to recruit E3 ubiquitin ligases such as VHL, Cereblon, and the IAPs to the target protein to be ubiquitinated. In this review, we describe some of the foundational studies underpinning the use of heterobivalent degraders for targeted protein degradation. We also present a framework for degraders as programmable essential activators of ubiquitin ligase enzymes, connecting their features as catalysts with established enzymology concepts.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A single degrader molecule can cycle through multiple binding and degradation events, enabling sub-stoichiometric activity.
“Moreover, a single degrader molecule can cycle through multiple binding and degradation events, enabling sub-stoichiometric activity141.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [141]
PROTACs can achieve high cellular potency due to their catalytic rather than occupancy-based mechanism of action.
“PROTACs can achieve high cellular potency due to their catalytic rather than occupancy-based mechanism of action 11,14,22”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [11]
The citation lists haven’t been fetched yet
References 84 · Cited by 126
- Authors
- Fisher, S. L., & Phillips, A. J.
- Affiliations
- C4 Therapeutics (United States) (US)
- Corresponding author
- Phillips, Andrew J
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 44
- Pages
- 47-55
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2807101583
- Cited by
- 126
- References
- 84
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 8 · 2023: 22 · 2022: 17 · 2021: 25 · 2020: 20 · 2019: 19 · 2018: 1
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Keywords
- targeted protein degradation, E3 ubiquitin ligase, ubiquitination, proteasome, VHL, cereblon, IAP, enzyme catalysis, small-molecule catalysts, drug discovery
- MeSH terms
- Animals, Humans, Ubiquitin, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Small Molecule Libraries, Ubiquitination, Drug Discovery, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review